Depo-Provera suspension. 150 mg/ml 1 ml

Depo-Provera is an antitumor drug, gestagen-depo form.

It has no androgenic and estrogenic activity. Depo-Provera inhibits the secretion of gonadotropic hormones (especially LH). In small doses it suppresses ovulation.

It has an inhibitory effect on the changes necessary to prepare the endometrium for implantation of the fertilized egg and increases the viscosity of cervical mucus.

Depo-Provera at higher doses has antitumor effects in hormone-sensitive malignancies. This effect appears to be due to action on steroid hormone receptors and on the pituitary-gonadal system.

Indications

Complementary and palliative treatment for recurrent and metastatic endometrial or renal cancer; palliative treatment for hormone-dependent forms of recurrent breast cancer in postmenopausal women.

Active ingredient

Composition

1 ml of suspension contains:

The active ingredient:

methylprednisolone acetate 150 mg;

Associates:

Polyethylene glycol 3350;

Polysorbate 80;

Sodium chloride;

methylparaben;

propylparaben;

water for injection.

How to take, the dosage

It is set individually, depending on the indication, stage of the disease, and the therapy regimen.

In endometrial cancer and renal cancer, the initial dose is 400-1000 mg per week in m/m. If within a few weeks or months there is improvement and stabilization of the process is achieved, maintenance therapy is prescribed at a dose of 400 mg per month.

In breast cancer, the drug is administered by m/m in an initial dose of 500 mg per day for 28 days. Then, maintenance doses of 500 mg twice a week are used. Treatment is continued until there are signs of disease progression.

Shake the bottle well before use to give a smooth suspension of the drug.

Special Instructions

The dosage form used must be closely matched to the indications for use.

Medroxyprogesterone should be used with particular caution in patients with thrombophlebitis, thromboembolic complications, severe liver dysfunction, and hypercalcemia.

Before using medroxyprogesterone for the treatment of gynecological diseases and contraception, the patient must rule out the presence of a tumor of the genitals or mammary glands.

If a pathohistological examination of certain organs and tissues is performed, the histologist should be warned about previous treatment with progestagens. Against the background of medroxyprogesterone use the results of the following studies may change: determination of gonadotropin levels; determination of progesterone, cortisol, testosterone (in men), estrogen (in women) levels in blood plasma; determination of pregnandiol levels in urine; conducting a sugar load test; conducting a metapyrone test.

Contraindications

Hypersensitivity to the components of the drug, pregnancy, lactation.

Side effects

Allergic reactions: anaphylaxis and anaphylactoid reactions, urticaria.

With the blood clotting system: thromboembolism, thrombophlebitis.

CNS disorders: increased nervous excitability, insomnia, drowsiness, fatigue, depression, dizziness, headache.

Dermatological reactions: itching, rash, acne, hirsutism and alopecia.

Perior genital system disorders: dysfunctional uterine bleeding, bloody discharge from the genital tract, amenorrhea, decreased libido or anorgasmia, vaginitis, celiac ulcers, hot flashes, abdominal pain, breast pain, galactorrhea.

In the digestive system: pain or discomfort in the abdomen, nausea, flatulence.

Muscular system disorders: cramps of the calf muscles, back and joint pain.

Others: asthenia, hyperthermia, change in body weight and moon-shaped face.